BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33864131)

  • 1. Clearance of buprenorphine during pregnancy and neonatal outcomes.
    Coker JL; Ray-Griffith SL; McLeod C; Han X; Mancino M; Kearns GL; Stowe ZN
    Arch Womens Ment Health; 2021 Dec; 24(6):933-939. PubMed ID: 33864131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine.
    Zhang H; Bastian JR; Zhao W; Chen H; Shaik IH; Chaphekar N; Caritis SN; Venkataramanan R
    Ther Drug Monit; 2020 Apr; 42(2):264-270. PubMed ID: 31929398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model.
    Wallin CM; Bowen SE; Roberge CL; Richardson LM; Brummelte S
    Drug Alcohol Depend; 2019 Dec; 205():107625. PubMed ID: 31706250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations.
    Winhusen T; Lofwall M; Jones HE; Wilder C; Lindblad R; Schiff DM; Wexelblatt S; Merhar S; Murphy SM; Greenfield SF; Terplan M; Wachman EM; Kropp F; Theobald J; Lewis M; Matthews AG; Guille C; Silverstein M; Rosa C
    Contemp Clin Trials; 2020 Jun; 93():106014. PubMed ID: 32353544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
    Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H
    Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
    Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
    J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnant and Postpartum Individuals' Knowledge, Attitudes, and Perceptions of Extended-release Buprenorphine for Treatment of Opioid Use Disorder.
    Lai M; Bowman J; Charles J; Smid MC
    J Addict Med; 2023 May-Jun 01; 17(3):342-345. PubMed ID: 37267186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.
    Concheiro M; Jones HE; Johnson RE; Choo R; Huestis MA
    Ther Drug Monit; 2011 Oct; 33(5):619-26. PubMed ID: 21860340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gestational changes in buprenorphine exposure: A physiologically-based pharmacokinetic analysis.
    Zhang H; Kalluri HV; Bastian JR; Chen H; Alshabi A; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2018 Sep; 84(9):2075-2087. PubMed ID: 29873094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment.
    Kacinko SL; Jones HE; Johnson RE; Choo RE; Concheiro-Guisan M; Huestis MA
    Clin Chem; 2009 Jun; 55(6):1177-87. PubMed ID: 19325013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Once-monthly Injectable Buprenorphine for the Treatment of Opioid Use Disorder in Postpartum Women: A Case Series.
    Shadowen C; Moeller FG; Martin CE
    J Addict Med; 2021 Jul-Aug 01; 15(4):292-296. PubMed ID: 34397780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.
    Bastian JR; Chen H; Zhang H; Rothenberger S; Tarter R; English D; Venkataramanan R; Caritis SN
    Am J Obstet Gynecol; 2017 Jan; 216(1):64.e1-64.e7. PubMed ID: 27687214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplified processing and rapid quantification of buprenorphine, norbuprenorphine, and their conjugated metabolites in human plasma using UPLC-MS/MS: Assessment of buprenorphine exposure during opioid use disorder treatment.
    Zhao W; Alshogran OY; Zhang H; Joshi A; Krans EE; Caritis S; Shaik IH; Venkataramanan R
    J Mass Spectrom; 2024 Apr; 59(4):e5015. PubMed ID: 38501738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perinatal morphine but not buprenorphine affects gestational and offspring neurobehavioral outcomes in mice.
    Smith BL; Hassler A; Lloyd KR; Reyes TM
    Neurotoxicology; 2023 Dec; 99():292-304. PubMed ID: 37981055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative Management of Buprenorphine: Solving the Conundrum.
    Quaye AN; Zhang Y
    Pain Med; 2019 Jul; 20(7):1395-1408. PubMed ID: 30500943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
    Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of opioid dependence with buprenorphine: current update.
    Soyka M
    Dialogues Clin Neurosci; 2017 Sep; 19(3):299-308. PubMed ID: 29302227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.